Obinutuzumab, also known as GA101, represents an novel monoclonal antibody designed in treat CLL. It targets CD20 expressed on B lymphocytes, resulting in antibody-dependent cell-mediated cytotoxicity and destruction. https://www.targetmol.com/compound/obinutuzumab
Obinutuzumab (GA101): A Comprehensive Overview
Internet - 4 hours ago 949142501869759Web Directory Categories
Web Directory Search
New Site Listings